

Virginia Espina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/38569/publications.pdf>

Version: 2024-02-01

157
papers

11,793
citations

36303

51
h-index

27406

106
g-index

161
all docs

161
docs citations

161
times ranked

19247
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
2	Proteomic Analysis of Cardioembolic and Large Artery Atherosclerotic Clots Using Reverse Phase Protein Array Technology Reveals Key Cellular Interactions Within Clot Microenvironments. <i>Cureus</i> , 2021, 13, e13499.	0.5	4
3	Protocol for the Mason: Health Starts Here prospective cohort study of young adult college students. <i>BMC Public Health</i> , 2021, 21, 897.	2.9	8
4	Local production of lactate, ribose phosphate, and amino acids by human triple-negative breast cancer. <i>Med</i> , 2021, 2, 736-754.e6.	4.4	28
5	Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7233-7241.	2.8	12
6	Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine. <i>Expert Review of Proteomics</i> , 2021, 18, 845-861.	3.0	19
7	Reverse Phase Protein Arrays. <i>Methods in Molecular Biology</i> , 2021, 2237, 103-122.	0.9	2
8	Clinical proteomics and molecular pathology. , 2020, , 149-163.		0
9	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. <i>Scientific Reports</i> , 2020, 10, 13944.	3.3	8
10	Evaluation of pathogen specific urinary peptides in tick-borne illnesses. <i>Scientific Reports</i> , 2020, 10, 19340.	3.3	8
11	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. <i>Clinical Cancer Research</i> , 2020, 26, 3126-3134.	7.0	133
12	Tumor-Draining Lymph Secretome En Route to the Regional Lymph Node in Breast Cancer Metastasis. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 57-67.	1.8	4
13	Characterization and Validation of Arg286 Residue of IL-1RAcP as a Potential Drug Target for Osteoarthritis. <i>Frontiers in Chemistry</i> , 2020, 8, 601477.	3.6	1
14	Proteomics for cancer drug design. <i>Expert Review of Proteomics</i> , 2019, 16, 647-664.	3.0	9
15	Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	3.0	2
16	Different measures of HMGB1 location in cancer immunology. <i>Methods in Enzymology</i> , 2019, 629, 195-217.	1.0	11
17	A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance. <i>Scientific Reports</i> , 2019, 9, 17380.	3.3	10
18	Unlocking bone for proteomic analysis and FISH. <i>Laboratory Investigation</i> , 2019, 99, 708-721.	3.7	5

#	ARTICLE	IF	CITATIONS
19	RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1188, 1-19.	1.6	13
20	Solid Pin Protein Array Printing Platforms. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1188, 61-75.	1.6	0
21	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , 2018, 15, 131-152.	3.0	63
22	Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment. <i>Journal of Translational Medicine</i> , 2018, 16, 89.	4.4	8
23	Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication. <i>Viruses</i> , 2018, 10, 191.	3.3	4
24	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. <i>BMC Cancer</i> , 2018, 18, 965.	2.6	21
25	<i>Clinical Proteomics and Molecular Pathology</i> . , 2018, , 183-203.		0
26	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , 2017, 15, 281-293.	3.4	16
27	Dual-Color, Multiplex Analysis of Protein Microarrays for Precision Medicine. <i>Methods in Molecular Biology</i> , 2017, 1550, 149-170.	0.9	4
28	One-Step Preservation and Decalcification of Bony Tissue for Molecular Profiling. <i>Methods in Molecular Biology</i> , 2017, 1606, 85-102.	0.9	2
29	Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis. <i>Antiviral Research</i> , 2017, 143, 162-175.	4.1	17
30	Potential anti-cancer activity of 7- O -pentyl quercetin: Efficient, membrane-targeted kinase inhibition and pro-oxidant effect. <i>Pharmacological Research</i> , 2017, 124, 9-19.	7.1	10
31	Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacytidine in High-Risk Myelodysplasia. <i>Frontiers in Pharmacology</i> , 2017, 8, 204.	3.5	19
32	Immune-modulating Activity of Hydrogel Microparticles Contributes to the Host Defense in a Murine Model of Cutaneous Anthrax. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 62.	3.5	1
33	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. <i>Oncotarget</i> , 2017, 8, 85120-85135.	1.8	15
34	Chemokine-Releasing Microparticles Improve Bacterial Clearance and Survival of Anthrax Spore-Challenged Mice. <i>PLoS ONE</i> , 2016, 11, e0163163.	2.5	5
35	Current state of the art for enhancing urine biomarker discovery. <i>Expert Review of Proteomics</i> , 2016, 13, 609-626.	3.0	101
36	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2016, 2, 395.	7.1	1

#	ARTICLE	IF	CITATIONS
37	PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E282-90.	7.1	70
38	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016, 30, 513-517.	7.2	3
39	High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 54-65.	3.0	27
40	Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis. <i>Journal of Translational Medicine</i> , 2015, 13, 346.	4.4	46
41	Nitric oxide as a regulator of <i>B. anthracis</i> pathogenicity. <i>Frontiers in Microbiology</i> , 2015, 6, 921.	3.5	12
42	Reverse-Phase Microarray Analysis Reveals Novel Targets in Lymph Nodes of <i>Bacillus anthracis</i> Spore-Challenged Mice. <i>PLoS ONE</i> , 2015, 10, e0129860.	2.5	6
43	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 4402-4410.	1.5	187
44	Chemokine-Releasing Nanoparticles for Manipulation of the Lymph Node Microenvironment. <i>Nanomaterials</i> , 2015, 5, 298-320.	4.1	10
45	Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 619-630.	3.8	39
46	Students Who Demonstrate Strong Talent and Interest in STEM Are Initially Attracted to STEM through Extracurricular Experiences. <i>CBE Life Sciences Education</i> , 2014, 13, 687-697.	2.3	50
47	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 15-24.	3.3	20
48	Glioblastoma Cell Enrichment Is Critical for Analysis of Phosphorylated Drug Targets and Proteomic-Genomic Correlations. <i>Cancer Research</i> , 2014, 74, 818-828.	0.9	44
49	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014, 11, 237-249.	3.0	9
50	Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces. <i>Nature Communications</i> , 2014, 5, 4413.	12.8	45
51	Non-enzymatic, Serum-free Tissue Culture of Pre-invasive Breast Lesions for Spontaneous Generation of Mammospheres. <i>Journal of Visualized Experiments</i> , 2014, , e51926.	0.3	0
52	Hydrogel Nanoparticle Harvesting of Plasma or Urine for Detecting Low Abundance Proteins. <i>Journal of Visualized Experiments</i> , 2014, , e51789.	0.3	9
53	Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. <i>Proteomics - Clinical Applications</i> , 2014, 8, 924-931.	1.6	22
54	Whole Proteome Analysis of Mouse Lymph Nodes in Cutaneous Anthrax. <i>PLoS ONE</i> , 2014, 9, e110873.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Reverse Phase Protein Microarray Technology. , 2013, , 349-361.		0
56	Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress. <i>Experimental Cell Research</i> , 2013, 319, 2113-2123.	2.6	105
57	Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. <i>BMC Research Notes</i> , 2013, 6, 507.	1.4	59
58	Attacking Breast Cancer at the Preinvasion Stage by Targeting Autophagy. <i>Women's Health</i> , 2013, 9, 157-170.	1.5	8
59	Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2473-2485.	7.0	31
60	Chloroquine enjoys a renaissance as an antineoplastic therapy. <i>Clinical Investigation</i> , 2013, 3, 743-761.	0.0	7
61	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. <i>Clinical Cancer Research</i> , 2012, 18, 6426-6435.	7.0	110
62	Reduction of Preanalytical Variability in Specimen Procurement for Molecular Profiling. <i>Methods in Molecular Biology</i> , 2012, 823, 49-57.	0.9	14
63	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
64	Laser Capture Microdissection for Protein and NanoString RNA Analysis. <i>Methods in Molecular Biology</i> , 2012, 931, 213-257.	0.9	49
65	Ductal Carcinoma In Situ: Challenges, Opportunities, and Uncharted Waters. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 40-44.	3.8	6
66	Laser Capture Microdissection: ArcturusXT Infrared Capture and UV Cutting Methods. <i>Methods in Molecular Biology</i> , 2012, 823, 157-178.	0.9	26
67	Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. <i>BioTechniques</i> , 2012, 0, 1-7.	1.8	27
68	Beyond Punishment: Doping, Deterrence, and Moral Disengagement. , 2012, 02, .		9
69	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. <i>Blood</i> , 2012, 120, 930-930.	1.4	0
70	2.29 Circulating CLL Cells Expressing Markers of Clinical Aggressiveness Display a Phosphoproteomic Profile Consistent with a Constitutive Receptor Engagement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S177-S178.	0.4	0
71	Multifunctional Core-Shell Nanoparticles: Discovery of Previously Invisible Biomarkers. <i>Journal of the American Chemical Society</i> , 2011, 133, 19178-19188.	13.7	90
72	Phosphoprotein Stability in Clinical Tissue and Its Relevance for Reverse Phase Protein Microarray Technology. <i>Methods in Molecular Biology</i> , 2011, 785, 23-43.	0.9	24

#	ARTICLE	IF	CITATIONS
73	A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. <i>Experimental Dermatology</i> , 2011, 20, 29-34.	2.9	46
74	A response to the two faces of autophagy in DCIS. <i>Nature Reviews Cancer</i> , 2011, 11, 618-618.	28.4	0
75	What is the malignant nature of human ductal carcinoma in situ?. <i>Nature Reviews Cancer</i> , 2011, 11, 68-75.	28.4	89
76	The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. <i>Biomaterials</i> , 2011, 32, 1157-1166.	11.4	52
77	Reverse Phase Protein Microarrays: Fluorometric and Colorimetric Detection. <i>Methods in Molecular Biology</i> , 2011, 723, 275-301.	0.9	20
78	One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens. <i>PLoS ONE</i> , 2011, 6, e23780.	2.5	71
79	Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,. <i>Blood</i> , 2011, 118, 3818-3818.	1.4	4
80	The Heme Degradation Pathway is a Promising Serum Biomarker Source for the Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1081-1091.	2.6	50
81	<i>Clinical Proteomics and Molecular Pathology.</i> , 2010, , 113-123.		0
82	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. <i>PLoS ONE</i> , 2010, 5, e13552.	2.5	42
83	Reverse-Phase Phosphoproteome Analysis of Signaling Pathways Induced by Rift Valley Fever Virus in Human Small Airway Epithelial Cells. <i>PLoS ONE</i> , 2010, 5, e13805.	2.5	49
84	Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem Cells. <i>Cancer Research</i> , 2010, 70, 8874-8885.	0.9	197
85	Reverse phase protein microarrays advance to use in clinical trials. <i>Molecular Oncology</i> , 2010, 4, 461-481.	4.6	126
86	Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival. <i>PLoS ONE</i> , 2010, 5, e10240.	2.5	124
87	Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines. <i>Blood</i> , 2010, 116, 4468-4468.	1.4	0
88	Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma. <i>Blood</i> , 2010, 116, 1920-1920.	1.4	0
89	<i>Clinical Proteomics and Molecular Pathology.</i> , 2009, , 165-183.		2
90	Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers. <i>PLoS ONE</i> , 2009, 4, e4763.	2.5	92

#	ARTICLE	IF	CITATIONS
91	Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD. <i>JAMA Ophthalmology</i> , 2009, 127, 613.	2.4	37
92	Quantitative cell signalling analysis reveals downâ€regulation of MAPK pathway activation in colorectal cancer. <i>Journal of Pathology</i> , 2009, 218, 514-519.	4.5	60
93	Tissue is alive: New technologies are needed to address the problems of protein biomarker preâ€analytical variability. <i>Proteomics - Clinical Applications</i> , 2009, 3, 874-882.	1.6	79
94	Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. <i>FEMS Immunology and Medical Microbiology</i> , 2009, 56, 129-142.	2.7	23
95	Reverse-Phase Protein Microarrays for Theranostics and Patient Tailored Therapy. <i>Methods in Molecular Biology</i> , 2009, 520, 89-105.	0.9	35
96	Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. <i>Drug Testing and Analysis</i> , 2009, 1, 447-454.	2.6	25
97	Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. <i>Journal of Materials Chemistry</i> , 2009, 19, 5071.	6.7	23
98	Application of Laser Microdissection and Reverse-Phase Protein Microarrays to the Molecular Profiling of Cancer Signal Pathway Networks in the Tissue Microenvironment. <i>Clinics in Laboratory Medicine</i> , 2009, 29, 1-13.	1.4	30
99	Comparison of Global versus Epidermal Growth Factor Receptor Pathway Profiling for Prediction of Lapatinib Sensitivity in Bladder Cancer. <i>Neoplasia</i> , 2009, 11, 1185-IN20.	5.3	29
100	Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations.. <i>Blood</i> , 2009, 114, 2860-2860.	1.4	0
101	Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles. <i>Nano Research</i> , 2008, 1, 502-518.	10.4	55
102	Smart Hydrogel Particles:â€ Biomarker Harvesting:â€ One-Step Affinity Purification, Size Exclusion, and Protection against Degradation. <i>Nano Letters</i> , 2008, 8, 350-361.	9.1	182
103	Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy. <i>Journal of Proteome Research</i> , 2008, 7, 1508-1517.	3.7	128
104	A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1998-2018.	3.8	187
105	Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1902-1924.	3.8	103
106	Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 177-186.	1.6	17
107	Automated Laser Capture Microdissection for Tissue Proteomics. <i>Methods in Molecular Biology</i> , 2008, 441, 71-90.	0.9	17
108	Reverse Phase Protein Microarrays for Theranostics and Patient-Tailored Therapy. <i>Methods in Molecular Biology</i> , 2008, 441, 113-128.	0.9	23

#	ARTICLE	IF	CITATIONS
109	Clinical Proteomics. , 2008, , 231-239.		0
110	Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival. Cancer Research, 2007, 67, 3431-3440.	0.9	230
111	Laser capture microdissection technology. Expert Review of Molecular Diagnostics, 2007, 7, 647-657.	3.1	161
112	Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Review of Molecular Diagnostics, 2007, 7, 625-633.	3.1	77
113	A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer, 2007, 109, 1323-1330.	4.1	134
114	The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer, 2007, 111, 173-184.	4.1	78
115	A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer. Cancer, 2007, 110, 309-317.	4.1	59
116	Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials, 2007, 28, 550-558.	11.4	66
117	Reverse Phase Protein Microarrays for Monitoring Biological Responses. , 2007, 383, 321-336.		26
118	Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics and Proteomics, 2007, 4, 157-64.	2.0	12
119	Role of proteomics in personalized medicine. Personalized Medicine, 2006, 3, 223-226.	1.5	2
120	Laser-capture microdissection. Nature Protocols, 2006, 1, 586-603.	12.0	651
121	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. Targeted Oncology, 2006, 1, 151.	3.6	2
122	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 2006, 34, 796-801.	0.4	74
123	Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling. Clinical Cancer Research, 2006, 12, 791-799.	7.0	75
124	Laser Capture Microdissection. Methods in Molecular Biology, 2006, 319, 213-229.	0.9	56
125	Laser Capture Microdissection. , 2006, , 339-344.		1
126	Proteomics of breast cancer. , 2006, , 101-113.		0

#	ARTICLE	IF	CITATIONS
127	Alterations of Cell Signaling Pathways in Pediatric B-ALL Patients.. Blood, 2006, 108, 4427-4427.	1.4	0
128	Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer, 2005, 103, 2313-2319.	4.1	32
129	Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling. Cancer, 2005, 105, 483-491.	4.1	7
130	An Interventional Magnetic Resonance Imaging Technique for the Molecular Characterization of Intraprostatic Dynamic Contrast Enhancement. Molecular Imaging, 2005, 4, 153535002005041.	1.4	14
131	A Transforming Growth Factor- β Receptor-Interacting Protein Frequently Mutated in Human Ovarian Cancer. Cancer Research, 2005, 65, 6526-6533.	0.9	58
132	Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy. Journal of Clinical Oncology, 2005, 23, 3614-3621.	1.6	170
133	Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma. Clinical Cancer Research, 2005, 11, 5847-5855.	7.0	105
134	Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma. Molecular and Cellular Proteomics, 2005, 4, 346-355.	3.8	278
135	Pegylated, Steptavidin-Conjugated Quantum Dots Are Effective Detection Elements for Reverse-Phase Protein Microarrays. Bioconjugate Chemistry, 2005, 16, 559-566.	3.6	124
136	Pathology of the Future: Molecular Profiling for Targeted Therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	61
137	CSF proteome: a protein repository for potential biomarker identification. Expert Review of Proteomics, 2005, 2, 57-70.	3.0	113
138	Protein pathway analysis in Clinical Proteomics using protein microarrays. Drug Discovery Today: Technologies, 2005, 2, 353-359.	4.0	1
139	Pathology of the Future: Molecular Profiling for Targeted Therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	4
140	Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. Journal of Clinical Investigation, 2005, 115, 1163-1176.	8.2	338
141	An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. Molecular Imaging, 2005, 4, 63-6.	1.4	7
142	Pathology of the future: molecular profiling for targeted therapy. Cancer Investigation, 2005, 23, 36-46.	1.3	8
143	APPLICATION OF LASER CAPTURE MICRODISSECTION AND PROTEIN MICROARRAY TECHNOLOGIES IN THE MOLECULAR ANALYSIS OF AIRWAY INJURY FOLLOWING POLLUTION PARTICLE EXPOSURE. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 851-861.	2.3	13
144	Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery, 2004, 135, 243-247.	1.9	29

#	ARTICLE	IF	CITATIONS
145	Protein microarray detection strategies: focus on direct detection technologies. Journal of Immunological Methods, 2004, 290, 121-133.	1.4	171
146	Application of sector protein microarrays to clinical samples. Clinical Proteomics, 2004, 1, 91-99.	2.1	4
147	Use of proteomic analysis to monitor responses to biological therapies. Expert Opinion on Biological Therapy, 2004, 4, 83-93.	3.1	85
148	Serum Proteomics in Cancer Diagnosis and Management. Annual Review of Medicine, 2004, 55, 97-112.	12.2	141
149	Clinical Proteomics: Revolutionizing Disease Detection and Patient Tailoring Therapy. Journal of Proteome Research, 2004, 3, 209-217.	3.7	108
150	Genomic and proteomic technologies for individualisation and improvement of cancer treatment. European Journal of Cancer, 2004, 40, 2623-2632.	2.8	86
151	Biomarkers of ovarian tumours. European Journal of Cancer, 2004, 40, 2604-2612.	2.8	72
152	Protein Microarrays. , 2004, , 1083-1088.		0
153	Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell, 2003, 3, 317-325.	16.8	439
154	Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics, 2003, 3, 2091-2100.	2.2	227
155	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14229-14234.	7.1	463
156	Molecular Diagnostics. Hematology American Society of Hematology Education Program, 2003, 2003, 279-293.	2.5	19
157	Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy. , 0, , 475-485.		0